Pulmonary Embolism Drugs Market Size & Share, by Drug Class (Thrombolytics, Thrombosis, Heparins, Thrombin Inhibitors); Distribution Channel (Hospital Pharmacy, Drug Store, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3400
  • Published Date: Mar 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Pulmonary Embolism Drugs Landscape

    • Janssen Global Services, LLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Siemens Healthcare GmbH
    • Baxter International Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Janssen Pharmaceuticals, Inc. revealed the results from Phase 3 A DUE study. This Phase 3 study is to represent investigational single-tablet combination therapy.

  • Novartis AG got approval for Tafinlar (dabrafenib) + Mekinist (trametinib) from U.S. Food and Drug Administration (FDA). These medications are used to treat pediatric patients or people with brain cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3400
  • Published Date: Mar 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing incidences of heart failure and increasing prevalence of pulmonary embolism (PE) are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

The higher possibility of blood clotting and lack of awareness regarding pulmonary embolism drugs are estimated to be the growth-hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Pfizer Inc., Sanofi S.A., Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Siemens Healthcare GmbH, Baxter International Inc, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, distribution channel, and by region.

The thrombosis segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying